V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Quanterix Executive Compensation (FY25)

QTRX · Executive and director compensation, fiscal 2022 to 2025
Latest say-on-pay support
=
June 9, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Quanterix

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 10, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Quanterix brief$1,500Get the executive brief
Velarion Member, one year
182 figures on this page: 177 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

More on Quanterix

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Masoud Toloue: $6,433,027 → $5,250,745 (18.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
What was Quanterix's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 87.7% of votes cast for or against in favor at the meeting held June 9, 2026.
Which companies are in Quanterix's peer group?
The disclosed peer group includes 10X Genomics, Adaptive Biotechnologies Corporation, Castle Biosciences, Inc., Cryoport, Inc. and Cytek Biosciences, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Masoud Toloue
President and Chief Executive Officer
◇—◇◇◇—◇◇
E. Kevin Hrusovsky
Former Executive Chairman and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Michael Doyle
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Mark Roskey
Chief Science and Collaboration Officer
◇—◇◇◇—◇◇
John Fry
Former General Counsel and Secretary
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Masoud Toloue
Former President and Chief Executive Officer
◇—◇◇◇—◇◇
Vandana Sriram
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Masoud Toloue
Former President and Chief Executive Officer
◇—◇◇◇—◇◇
Vandana Sriram
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Masoud Toloue
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Vandana Sriram
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
William Donnelly
Former Executive Chair
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Masoud ToloueOPTION◇——◇—◇◇
Masoud ToloueRSU◇——◇——◇
Vandana SriramOPTION◇——◇—◇◇
Vandana SriramRSU◇——◇——◇
William P. DonnellyRSU◇——◇——◇
William P. DonnellyOPTION◇——◇—◇◇
William P. DonnellyOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Vandana SriramRSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Vandana Sriram
Chief Financial Officer and Treasurer · Employment agreement
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Scott Mendel
◇◇◇———◇
Myla Lai-Goldman, M.D
◇◇◇———◇
Garret M. Hampton, Ph.D
◇◇————◇
Alan Sachs, M.D., Ph.D
◇◇————◇
Jeffrey T. Elliott
Lead independent director
◇◇◇———◇
Karen A. Flynn
◇◇◇———◇
Ivana Magovevcic-Liebisch, Ph.D., J.D
◇◇◇———◇
Paul M. Meister
◇◇◇———◇
David R. Walt, Ph.D
◇◇◇———◇
Martin D. Madaus, Ph.D
◇◇◇———◇
Sarah E. Hlavinka
◇◇◇———◇
Everett Cunningham and William P. Donnelly served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board equity retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance member◇
Stock ownership guideline: Non-Employee Director 5x annual base cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10X Genomics TXG
  • Adaptive Biotechnologies Corporation ADPT
  • Castle Biosciences, Inc. CSTL
  • Cryoport, Inc. CYRX
  • Cytek Biosciences, Inc. CTKB
  • Maravai LifeSciences Holdings, Inc. MRVI
  • Mesa Laboratories, Inc. MLAB
  • Nautilus Biotechnology, Inc. NAUT
  • OmniAb, Inc. OABI
  • Pacific Biosciences of California, Inc. PACB
  • Quantum-Si Incorporated QSI
  • Standard BioTools Inc. LAB
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2024September 29, 2025=◇◇◇
2023June 3, 2024=◇◇◇
2022June 7, 2023=◇◇◇
2021June 23, 2022=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Masoud Toloue (Former President and Chief Executive Officer), FY2025 total compensation $5,250,745 (base salary $670,950) [exec_comp, SEC accession 0001104659-26-048166, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Quanterix files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Quanterix disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Quanterix sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Quanterix's disclosed peer group is defensible, who names Quanterix back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
182 figures on this page: 177 cited to the filing that reported them, 5 calculated from figures it prints.
177 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001503274-26-000028
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-048166
    EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · Executive Officer and Director Compensation · Outstanding Equity Awards at 2025 Fiscal Year-End · Potential Payments upon Termination · and 2 more sections
  3. 0001503274-25-000097
  4. 0001104659-25-082586
    Summary Compensation Table
  5. 0001104659-24-069615
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001104659-24-047245
    Summary Compensation Table
  7. 0001104659-23-069375
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-23-045632
  9. 0001104659-22-074770
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Quanterix executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/QTRX (accessed 2026).
Short form: data: Velarion

The paid brief for Quanterix

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Quanterix and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Quanterix discloses

The companies named in QTRX's own disclosed peer group.

10X GenomicsAdaptive Biotechnologies CorporationCastle Biosciences, Inc.Cryoport, Inc.Cytek Biosciences, Inc.Maravai LifeSciences Holdings, Inc.Mesa Laboratories, Inc.Nautilus Biotechnology, Inc.OmniAb, Inc.Pacific Biosciences of California, Inc.Quantum-Si IncorporatedStandard BioTools Inc.Twist Bioscience CorporationVeracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy